Polyrizon has announced the initiation of its first clinical trial, a study of its Nasarix (PL-14) hydrogel nasal spray in patients with seasonal allergic rhinitis. In September 2025, the company said that it had submitted a pre-submission package to the FDA for the intranasal allergen blocker. Nasarix is based on Polyrizon’s Capture and Contain “biological mask” hydrogel technology.
The trial is expected to enroll approximately 120 patients with seasonal allergies who will self-administer either Nasarix or a saline nasal spray for up to 30 days. The primary endpoint will be the difference in mean daily reflective Total Nasal Symptom Score (rTNSS) at Day 14.
Polyrizon CEO Tomer Izraeli commented, “This is a defining milestone for Polyrizon. The enrollment of the first patient in our US study represents the culmination of extensive product development, preclinical evaluation, manufacturing and regulatory preparation, and moves Nasarix into clinical evaluation in patients for the first time. We believe this study represents an important step toward our goal of developing a differentiated, drug-free approach for people suffering from seasonal allergies.”
Chief Technology Officer Tidhar Turgeman said, “Moving the Nasarix Allergy Blocker into a first-in-human clinical study is an important step in the development of our Capture and Contain technology from concept through product development and preclinical evaluation. The study has been designed to generate data regarding efficacy and safety under real-world seasonal allergen exposure. We look forward to advancing enrollment across our US clinical sites and evaluating Nasarix’s potential as a drug-free option for patients with seasonal allergic rhinitis.”
Read the Polyrizon press release
